Edition:
United Kingdom

Mauna Kea Technologies SAS (MKEA.PA)

MKEA.PA on Paris Stock Exchange

1.50EUR
22 Aug 2019
Change (% chg)

-- (--)
Prev Close
€1.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
187,755
52-wk High
€3.44
52-wk Low
€1.41

Latest Key Developments (Source: Significant Developments)

Mauna Kea: Receipt Of 11.5 Million Euros Under New Financing Agreement With EIB
Wednesday, 3 Jul 2019 

July 3 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::MAUNA KEA ANNOUNCES RECEIPT OF €11.5 MILLION UNDER NEW FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK.RECEIVED FIRST TRANCHE OF EUR 11.5 MILLION UNDER FINANCING AGREEMENT EIB.COMPANY REDEEMED NON-DILUTIVE BOND FINANCING WITH IPF PARTNERS.FINANCING WITH IPF PARTNERS WAS COMPRISED OF TWO BOND TRANCHES OF EUR 4.0 MILLION AND EUR 5.0 MILLION.TRANCHE 1 IS COMPANIED BY ISSUANCE OF SHARE SUBSCRIPTION WARRANTS ("BSAS") ENTITLING HOLDER, IN EVENT OF EXERCISE, TO SUBSCRIBE FOR MAXIMUM OF 1,450,000 SHARES OF CO.FINANCING WITH IPF PARTNERS: COMPANY REPAID BOTH TRANCHES FULLY FOR TOTAL AMOUNT OF EUR 10.7 MILLION.SHARES ISSUED UPON EXERCISE OF WARRANTS WILL BE ADMITTED TO TRADING ON EURONEXT PARIS REGULATED MARKET.  Full Article

Mauna Kea Technologies FY Net Loss Widens To EUR 12.8 Million
Wednesday, 20 Mar 2019 

March 20 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::FY NET LOSS EUR 12.8 MILLION VERSUS LOSS OF EUR 10.2 MILLION YEAR AGO.FY OPERATING LOSS EUR 12.0 MILLION VERSUS LOSS OF EUR 9.7 MILLION YEAR AGO.CASH FLOW AMOUNTED TO € 8.6 MILLION AS OF DECEMBER 31, 2018.FY GROSS MARGIN STANDS AT 69.6% AGAINST 68.2% IN 2017.  Full Article

Mauna Kea Technologies Says CONTACT 2 Study Met Its Clinical Endpoints
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::PIVOTAL STUDY ON CONTACT 2 PANCREATIC CYSTS HAS MET ALL OF ITS PRIMARY AND SECONDARY CLINICAL ENDPOINTS.SIGNIFICANTLY HIGHER DIAGNOSTIC PERFORMANCE OF CELLVIZIO COMPARED TO THE STANDARD TECHNIQUE.CELLVIZIO MADE A CONCLUSIVE AND CORRECT DIAGNOSIS IN 21 OF THE 23 PATIENTS.  Full Article

Mauna Kea Technologies H1 Net Loss Widens To 6.8 Million Euros
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::H1 NET LOSS EUR 6.8 MILLION VERSUS LOSS EUR 5.8 MILLION YEAR AGO.CASH POSITION AT EUR 15.1 MILLION AS OF JUNE 30, 2018.H1 TOTAL REVENUE EUR 3.2 MILLION VERSUS EUR 3.8 MILLION YEAR AGO.H1 OPERATING LOSS EUR 6.5 MILLION VERSUS LOSS OF EUR 5.5 MILLION YEAR AGO.  Full Article

Mauna Kea Technologies Appoints Christophe Lamboeuf As Chief Financial Officer
Thursday, 5 Apr 2018 

April 5 (Reuters) - Mauna Kea Technologies SAS ::MAUNA KEA TECHNOLOGIES APPOINTS CHRISTOPHE LAMBOEUF, AN EXPERIENCED FINANCIAL EXECUTIVE, AS CHIEF FINANCIAL OFFICER.  Full Article

Mauna Kea Technologies Says Cellvizio Receives Positive Evaluation From Korean Health Authority
Thursday, 15 Mar 2018 

March 15 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::ANNOUNCES CELLVIZIO RECEIVES POSITIVE EVALUATION FROM KOREAN HEALTH AUTHORITY.RECOGNITION LEADS TO THE CREATION OF SPECIFIC REIMBURSEMENT CODES FOR CELLVIZIO PROCEDURES IN SOUTH KOREA.  Full Article

Mauna Kea Technologies Q4 Revenue Falls To 1.6 Million Euros
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::Q4 REVENUE EUR 1.6 MILLION VERSUS EUR 2.2 MILLION YEAR AGO.SOLID CASH POSITION OF € 20.6 MILLION AT THE END OF JANUARY 2018.  Full Article

Mauna Kea Receives FDA Clearance For Cellvizio 100 Series
Monday, 18 Dec 2017 

Dec 18 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::NEW FDA CLEARANCE VALIDATES IN VIVO, REAL-TIME “IDENTIFICATION OF CELLULAR AND VASCULAR ORGANIZATION AND ARCHITECTURE” USING CELLVIZIO®.‍PIVOTAL REGULATORY MILESTONE POSITIONING CELLVIZIO AS UNIQUE REAL-TIME IN VIVO VISUALIZATION SYSTEM​.  Full Article

Mauna Kea Technologies Implements Equity Financing Facility With Kepler Cheuvreux‍​
Friday, 1 Dec 2017 

Dec 1 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::IMPLEMENTATION OF A NEW EQUITY FINANCING FACILITY WITH KEPLER CHEUVREUX‍​.KEPLER CHEUVREUX TO SUBSCRIBE FOR 2,250,000 SHARES AT ITS OWN INITIATIVE OVER TIMEFRAME NOT EXCEEDING 24 MONTHS.  Full Article

Mauna Kea Technologies says new Contact study analysis demonstrates Cellvizio’s ability to improve management of patients with pancreatic cysts
Monday, 30 Oct 2017 

Oct 30 (Reuters) - MAUNA KEA TECHNOLOGIES SAS ::MAUNA KEA TECHNOLOGIES: NEW CONTACT STUDY ANALYSIS DEMONSTRATES CELLVIZIO’S ABILITY TO IMPROVE THE MANAGEMENT OF PATIENTS WITH PANCREATIC CYSTS.  Full Article